|
|
|
| home > white papers > Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles - NanoSight |
|
|
 WHITE PAPERS |
|
NanoSight
|
|
Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles
|
|
The study of exosomes and other cell-derived microvesicles is
an area of rapidly growing importance and the subject of intense interest and
research. The previous lack of suitable methods for their detection, analysis,
enumeration and phenotyping is proving to be a significant limitation in these
studies. This mini-review shows the degree to which the technique of
Nanoparticle Tracking Analysis (NTA) is helping to address these problems.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with their new integration
Philadelphia, PA – November 14, 2019: Signant Health,
formerly CRF Health and Bracket, is proud to announce that it has integrated
its industry leading eCOA platform TrialMax®, with ActiGraph’s CentrePoint system.
The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, helps simplify the process of
collecting and monitoring real-world activity, mobility, and sleep outcomes
data for patients and researchers.
More info >> |
|
 |
White Papers |
 |
|
Recommendations Sourcing Human Biospecimens
BioIVT
The foundations for protecting human research subjects come from the
ethical principles surrounding the Belmont report : Respect for persons,
beneficence, and justice. The use of human biospecimens in research
supports these principles with legal and ethical regulations - the most
important of which is permission.(1) This permission may come directly
from the donor or granted by others with authorization to protect the
interests of biospecimen donors.
More info >> |
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
|
|
